All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

GLP-1 adoption in Florida

Florida has an estimated 947,205 GLP-1 users across 67 counties. Average estimated adoption is 1.3 percentage points below the national rate of 5.7%.

Last reviewed |Reviewed by the FormBlends Editorial Standards Team

4.4%

Est. adoption rate

947,205

Est. users

32.2%

Avg adult obesity

21,634,529

Adult population

State facts for search and AI answers

What makes the Florida GLP-1 page useful

This page ties the statewide answer to county-level demand, coverage context, and practical access checks. The goal is to help readers move from a broad state estimate to the local county or provider question that actually matters.

State signal

Florida: 67 counties, 947,205 estimated GLP-1 users

State pages summarize the county-level demand model before readers drill into local pages.

Model inputs

Average adoption 4.4%; average adult obesity 32.2%

The model uses CDC PLACES obesity prevalence, Census population, and KFF national GLP-1 utilization.

Coverage context

Florida Medicaid does not cover GLP-1s for obesity. Coverage for T2D, cardiovascular disease, and sleep apnea indications is still available. According to KFF (2026-01-16), federal Medicaid rules require GLP-1 coverage for type 2 diabetes, cardiovascular disease, and sleep apnea indications. Obesity coverage is optional and varies by state.

Coverage policy can make real access higher or lower than projected local demand.

How to use this page

Find counties with the strongest demand signal, then verify coverage, provider access, and pharmacy source before starting care.

This is a local planning page, not a prescription recommendation.

Counties ranked by estimated adoption

Adoption strip: each bar is one county, tallest = highest estimated rate
County adoption strip. Tallest bar = highest projected adoption in Florida.
Ranked counties in Florida by estimated GLP-1 adoption.
RankCountyPopulationObesity %Est. adoptionEst. users
1Gadsden43,74644.5%6.1%2,651
2Liberty7,70444.2%6.0%464
3Okeechobee39,87044.1%6.0%2,392
4Hamilton13,49242.0%5.7%772
5DeSoto34,25841.8%5.7%1,949
6Union15,52441.5%5.7%877
7Taylor21,42140.9%5.6%1,193
8Hardee25,52840.6%5.5%1,412
9Polk736,22940.6%5.5%40,713
10Calhoun13,75339.9%5.4%747
11Washington25,01439.8%5.4%1,356
12Columbia69,83239.7%5.4%3,771
13Osceola393,74539.4%5.4%21,105
14Jackson47,70438.9%5.3%2,528
15Suwannee43,88138.6%5.3%2,304
16Highlands102,33938.4%5.2%5,352
17Wakulla33,73238.2%5.2%1,754
18Glades12,17937.9%5.2%628
19Madison17,98637.9%5.2%928
20Hendry39,90237.7%5.1%2,047
21Marion378,22537.1%5.0%19,100
22Holmes19,52936.5%5.0%971
23Escambia321,29636.4%5.0%15,904
24Hernando196,62136.4%5.0%9,733
25Lake386,82935.8%4.9%18,839
26Leon294,12835.6%4.8%14,265
27Lafayette8,10735.2%4.8%388
28Baker27,96935.1%4.8%1,337
29Gulf15,00235.1%4.8%717
30Bradford27,81635.0%4.8%1,324
31Jefferson14,45834.9%4.8%687
32Dixie16,73734.8%4.7%793
33Gilchrist18,07034.7%4.7%853
34Clay219,65034.5%4.7%10,324
35Duval995,70834.3%4.7%46,500
36Brevard610,72334.2%4.7%28,460
37Levy43,26833.8%4.6%1,990
38Orange1,427,40333.5%4.6%65,090
39Alachua279,72933.4%4.5%12,728
40Nassau91,53833.4%4.5%4,165
41Putnam73,60433.3%4.5%3,334
42Bay181,05533.2%4.5%8,184
43Volusia558,52033.2%4.5%25,245
44Citrus155,17332.9%4.5%6,952
45Manatee405,06932.7%4.5%18,026
46Franklin12,27632.4%4.4%541
47Sumter131,83232.0%4.4%5,748
48St. Lucie334,68231.9%4.3%14,525
49Pasco569,21131.8%4.3%24,647
50Pinellas959,91831.7%4.3%41,372
51Santa Rosa188,99431.7%4.3%8,146
52Charlotte189,90031.6%4.3%8,166
53Hillsborough1,468,56031.5%4.3%63,001
54Lee772,90231.2%4.3%32,848
55Flagler117,51530.9%4.2%4,947
56Okaloosa212,02130.8%4.2%8,884
57Broward1,940,90730.4%4.1%80,354
58Sarasota439,39230.3%4.1%18,103
59Walton76,61829.6%4.0%3,088
60Miami-Dade2,688,23729.3%4.0%107,261
61Seminole471,32129.3%4.0%18,806
62St. Johns278,72228.7%3.9%10,898
63Collier380,22128.0%3.8%14,486
64Martin159,39927.9%3.8%6,057
65Indian River160,98627.5%3.7%6,021
66Palm Beach1,494,80527.3%3.7%55,607
67Monroe82,04425.5%3.5%2,847

How Florida fits the national picture

The KFF 2024 poll pegged national adult GLP-1 use at 5.7%. Applied to Florida's obesity profile, the model projects 4.4% of adults are on a GLP-1 medication. That matches the county-level obesity data from CDC PLACES (2023) more than any measured prescription count; the state's real share could be higher in urban areas with broad commercial coverage, or lower in rural regions where prescriber access is limited.

Compounded semaglutide and tirzepatide complicate the picture. After the FDA shortage resolution in late 2024 and early 2025, compounded supply dropped sharply. Brand-name utilization rose. The county numbers here don't separate brand vs. compounded, because no public dataset does yet.

Decision path

How should I use the Florida GLP-1 map?

This state view is a demand and access signal, not a prescription recommendation. Use it to understand where GLP-1 need may be concentrated, then pressure-test provider availability, insurance rules, and pharmacy quality before starting care.

State
Florida
Counties
67
Est. users
947,205
Avg adoption
4.4%

Step 1

Find county context

County estimates help separate broad statewide demand from the local access picture a patient actually experiences.

Review counties

Step 2

Check coverage and price

Florida access depends on payer policy, prior authorization, cash-pay pricing, and whether local clinicians can support follow-up.

Check coverage path

Step 3

Decide on care route

If local access is thin or pricing is unclear, a supervised telehealth assessment can clarify eligibility and next steps.

Compare provider options
Start provider review in FloridaReview pharmacy oversight

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

CDC PLACES

Dataset

Used for county-level obesity inputs in local GLP-1 adoption estimates.

KFF GLP-1 utilization polling

Dataset

Used as the national anchor for estimated GLP-1 adoption.

STEP 1 semaglutide obesity trial

Trial

Primary trial source for semaglutide 2.4 mg weight-loss expectations and side effects.

Frequently asked questions

How is GLP-1 adoption calculated for Florida counties?
We multiply each county's CDC PLACES 2023 adult obesity prevalence by a scaling factor k = 0.1361, which comes from the KFF 2024 figure of 5.7% national GLP-1 adoption divided by the 41.9% national adult obesity rate. That gives an estimated per-county adoption %. Multiply by Census ACS 5-year 2022 county population to get projected users. Florida shows 4.4% state-average adoption under this model.
Why is Florida's number 1.3 percentage points below the national average?
Adult obesity prevalence in Florida averages 32.2% (CDC BRFSS 2024, state-level). The national average is 41.9%. The model links adoption linearly to obesity, so states above the national obesity rate come out above the national adoption estimate, and vice versa. Real variation also depends on commercial insurance coverage and Medicaid GLP-1 policy, both of which differ significantly by state.
Do Medicaid enrollees in Florida get GLP-1 coverage?
Florida Medicaid does not cover GLP-1s for obesity. Coverage for T2D, cardiovascular disease, and sleep apnea indications is still available. According to KFF (2026-01-16), federal Medicaid rules require GLP-1 coverage for type 2 diabetes, cardiovascular disease, and sleep apnea indications. Obesity coverage is optional and varies by state.
What studies back up GLP-1 weight loss expectations?
The STEP 1 trial (Wilding et al., NEJM, 2021) enrolled 1,961 adults on 2.4mg weekly semaglutide over 68 weeks and saw mean body weight change of negative 14.9% vs negative 2.4% on placebo. SURMOUNT-1 (Jastreboff et al., NEJM, 2022) tested tirzepatide in 2,539 adults over 72 weeks and saw negative 20.9% at 15mg weekly. Both were randomized, double-blind, and placebo-controlled.
How often does the Florida county data refresh?
CDC PLACES releases annually in late summer. Census ACS 5-year estimates release every December. KFF reruns its GLP-1 utilization poll roughly twice a year. We re-run the full county model whenever any of those update, and the last-reviewed date at the top of every page reflects the most recent refresh.

Sources

Related reading

glp1

Compounded Semaglutide Guide

How compounded semaglutide access works, what to ask a pharmacy, and how to compare safety and pricing.

glp1

Semaglutide Cost Comparison

Compare semaglutide pricing across brand, insurance, cash-pay, and compounded access paths.

experience

Tirzepatide Side Effects Complete Guide

Common tirzepatide side effects, warning signs, and practical management steps to discuss with a clinician.

glp1

Semaglutide Injection Sites

How to rotate semaglutide injection sites and reduce irritation, bruising, and technique problems.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

2026 GLP-1 Telehealth Report

105 providers scored on price, safety, compliance, and patient experience.

Compounded GLP-1 ZIP Lookup

State pharmacy-board posture and telehealth access for US ZIP codes.

America on GLP-1 Map

County-level adoption estimates using CDC, Census, and KFF inputs.

Looking for GLP-1 care in Florida?

FormBlends ships compounded semaglutide and tirzepatide to Florida with licensed telehealth consultations.

Start your assessment

Estimated adoption figures are modeled projections from public data, not measured prescription counts. This page is general information, not medical advice. Individual results vary. Talk to a licensed healthcare provider before starting any medication.